Outlook and Valuation: We forecast HCL to report healthy top-line CAGR of ~13% to `954cr over FY2019-22E on the back of government initiatives, new product launches, strong brand name and wide distribution network. On the bottom-line front (reported PAT), we estimate ~24% CAGR to `102cr due to strong revenue and operating margin improvement (on the